KIR3DL1 and B-cell chronic lymphocytic leukemia: In keeping with these observations, in vitro studies have shown that allogeneic NK cells, after expansion/activation with an optimized protocol, are able to kill CLL cells independently of KIR–HLA mismatches [270].